Latham & Watkins Advises on BridgeBio Pharma’s US$550 Million Convertible Senior Notes Offering

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a new type of biopharmaceutical company focused on genetic diseases, announced the pricing of US$550 million aggregate principal amount of 0.75% convertible senior notes due 2033 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. In connection with the offering, the company granted the initial purchasers an option to purchase up to an additional US$82.5 million aggregate principal amount of notes. The sale of the notes is expected to close on January 21, 2026, subject to customary closing conditions.

Latham & Watkins LLP represents the initial purchases in the offering with a Capital Markets team led by partners Greg Rodgers, Shayne Kennedy, and Ryan Gold, with associates Andrew Bentz and Steve Hess, and assistance from Sareen Ishanyan. Advice was also provided on tax matters by partners Elena Romanova and Aaron Bernstein, with associate Jack Santoro.